Skip to main content
. Author manuscript; available in PMC: 2014 Apr 25.
Published in final edited form as: Cancer Cell. 2012 Jan 17;21(1):66–81. doi: 10.1016/j.ccr.2011.11.024

Figure 2. Reduced tumor growth and increased metastasis after depletion of vessel-associated PDGFRβ+ cells.

Figure 2

(A) Orthotopic implantation of 4T1 cancer cells into PDGFRβ-tk mice and wildtype littermates, with daily ganciclovir (GCV) injections beginning when tumors reached ~500mm3. (B) Tumor volumes over the experimental timecourse. (C) Representative images of H&E-stained lung sections. Scale bar: 10µm. Arrows point to metastatic areas. High magnification images of metastatic nodules are located in the upper right corner. Scale bar: 50µm Percent metastatic area and number of metastatic lung nodules. (D) Representative images of immunostaining for PDGFRβ (red) and NG2 (green) tumor sections. DAPI=nuclei. Scale bar: 50µm. Quantitative assessment of vessel-associated PDGFRβ+, NG2+, PDGFRβ+/NG2+ double positive, and CD31+ cells in 4T1 tumors from PDGFRβ-tk+GCV and WT+GCV mice. (E) Tumor volumes over the experimental timecourse in mice treated with anti-PDGFRβ antibody or control IgG. (F) Number of metastatic lung nodules. (G) Representative images of tumor sections immunolabeled for PDGFRβ (green)/CD31 (red) in IgG-treated and anti- PDGFRβ-treated mice, and quantification of vessel-associated PDGFRβ+ cells in the tumors, scale bar: 50µm. Inserts are magnified images of selected area, scale bar: scale bar: 10µm. Error bars display SEM; *p<0.05. See also Figure S2.